Rodeo Therapeutics
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Therapeutics, Small-molecule drugs
- Stage
- startup
- Total raised
- $14.3M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $9M · Nov 2018 SEC Form D
Recent coverage
Front-page news, podcasts and videos about Rodeo Therapeutics
Seattle Biotech OncoResponse Raises $40.6M Series C to Develop Antibody-Based Cancer Treatments
Seattle biotech OncoResponse raised $40.6 million in a Series C round to develop antibody-based cancer immunotherapies, leveraging antibodies from patients with strong immunotherapy responses. Led by CEO Clifford Stocks, the company has now raised nearly $110 million since its 2015 launch.
Amgen to buy Seattle startup Rodeo Therapeutics for $55M upfront, up to $666M more in milestones
Amgen agreed to acquire Seattle biotech Rodeo Therapeutics, which develops small-molecule therapies to repair and regrow tissues, for $55 million upfront plus up to $666 million in contingent payments. Rodeo, led by CEO Thong Le and founded by Sanford Markowitz, Stanton Gerson and Joseph Ready, has backing from investors including AbbVie, Lilly, Arch Venture Partners and Johnson & Johnson and had raised over $14 million.
